Edition:
United Kingdom

Endo International PLC (ENDP.OQ)

ENDP.OQ on NASDAQ Stock Exchange Global Select Market

3.88USD
13 Sep 2019
Change (% chg)

-- (--)
Prev Close
$3.88
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,832,007
52-wk High
$18.50
52-wk Low
$1.97

Summary

Name Age Since Current Position

Roger Kimmel

72 2007 Independent Chairman of the Board

Paul Campanelli

57 2016 President, Chief Executive Officer, Director

Blaise Coleman

45 2016 Chief Financial Officer, Executive Vice President

Terrance Coughlin

54 2016 Chief Operating Officer, Executive Vice President

Patrick Barry

51 2018 Executive Vice President and Chief Commercial Officer

Domenico Ciarico

2019 Executive Vice President, Chief Commercial Officer - Sterile and Generics

Matthew Maletta

48 2015 Executive Vice President, Chief Legal Officer

Carrie Nichol

38 2018 Chief Accounting Officer, Vice President, Controller

Shane Cooke

56 2014 Independent Director

Nancy Hutson

69 2009 Independent Director

Michael Hyatt

73 2014 Independent Director

Sharad Mansukani

49 2018 Senior Independent Director

William Montague

72 2009 Independent Director

Biographies

Name Description

Roger Kimmel

Mr. Roger H. Kimmel is an Independent Chairman of the Board of Endo International Public Limited Company. He is Chairman of the Board of Endo and is a member of Endo’s Nominating & Governance Committee, a member of Endo’s Audit Committee and a member of Endo’s Compliance Committee. Mr. Kimmel became Chairman of the Board upon the Company’s inception in February 2014. Mr. Kimmel has been Vice Chairman of Rothschild Inc., an investment banking firm, since 2001. Previously, Mr. Kimmel was a partner of the law firm Latham & Watkins for more than five years. Mr. Kimmel was a Director of PG&E Corporation, a public energy-based holding company, and its subsidiary Pacific Gas and Electric Company, a utility company, from 2010 until January 2019, a Director of Schiff Nutrition International until 2012 and a Director and Chairman of Endo Health Solutions Inc. from 2000 until February 2014. Mr. Kimmel served as Chairman of the Board of Trustees of the University of Virginia Law School Foundation (not-for-profit) from 2009 to 2015. He has been a public speaker on corporate governance issues and private equity transactions. Since 2017, Mr. Kimmel has been a lecturer at the University of Virginia School of Law. Mr. Kimmel holds a Bachelor of Arts degree from the George Washington University and a J.D. degree from the University of Virginia School of Law.

Paul Campanelli

Mr. Paul V. Campanelli serve as President, Chief Executive Officer, Director of the Company., effective September 23, 2016. Mr. Campanelli joined Endo in September 2015 as the President of Par Pharmaceutical, leading Endo’s fully integrated U.S. Generics business, following Endo’s acquisition of Par Pharmaceutical. Prior to joining Endo, he had served as Chief Executive Officer of Par Pharmaceutical Companies, Inc. following the company’s acquisition by TPG in 2012. Prior to the TPG acquisition, Mr. Campanelli served as Chief Operating Officer and President of Par Pharmaceutical, Inc. from 2011 to 2012. At Par Pharmaceutical Inc., Mr. Campanelli had also served as Senior Vice President, Business Development & Licensing; Executive Vice President and President of Par Pharmaceutical, Inc.; and was named a Corporate Officer by its board of directors. He also served on the board of directors of Sky Growth Holdings Corporation. Prior to joining Par Pharmaceutical Companies Inc., Mr. Campanelli served as Vice President, Business Development at Dr. Reddy’s Laboratories Ltd., where he was employed from 1992 to 2001. Mr. Campanelli earned his Bachelor of Science degree from Springfield College.

Blaise Coleman

Mr. Blaise Coleman serves as Chief Financial Officer, Executive Vice President of the Company. Mr. Coleman was serving as Endo's Interim Chief Financial Officer since November 22, 2016. Mr. Coleman joined Endo in January 2015 as Vice President of Corporate Financial Planning & Analysis and was promoted to Senior Vice President of Global Finance Operations in November 2015. Prior to joining Endo, Mr. Coleman held a number of finance leadership roles with AstraZeneca, a global biopharmaceutical company, latterly as the Chief Financial Officer of the AstraZeneca/Bristol-Myers Squibb US Diabetes Alliance from January 2013 until January 2015. Prior to this, he was the Head of Finance for the AstraZeneca Global Medicines Development organization based in Mölndal, Sweden from September 2011 to January 2013. Mr. Coleman joined AstraZeneca as Senior Director Commercial Finance for the US Cardiovascular Business in November 2007. He joined AstraZeneca from Centocor, a wholly owned subsidiary of Johnson & Johnson, where he held positions in the respective Licenses & Acquisitions and Commercial Finance organizations. Mr. Coleman’s move to Centocor in early 2003 followed 7 years’ experience with the global public accounting firm, PricewaterhouseCoopers LLP. He is a Certified Public Accountant. Mr. Coleman received a Bachelor of Science in accounting from Widener University and a MBA from Duke University, The Fuqua School of Business.

Terrance Coughlin

Mr. Terrance John Coughlin is Chief Operating Officer, Executive Vice President of the Company. In this role, Mr. Coughlin has responsibility for Manufacturing and Technical Operations and R&D across the enterprise. Most recently, Mr. Coughlin served as Vice President, Operations of Par Pharmaceutical Companies, Inc., a subsidiary of Endo. Prior to Endo’s acquisition of Par in September 2015, Mr. Coughlin was the Chief Operating Officer of Par Pharmaceutical Companies, Inc. Prior to joining Par, Mr. Coughlin held a number of leadership roles with Glenmark Generics, Inc. USA/Glenmark Generics Limited latterly as the President and Chief Executive Officer of Glenmark Generics, Inc. USA/Glenmark Generics Limited. Prior to this, Mr. Coughlin had the overall responsibility for Glenmark’s North American, Western European and Eastern European generics businesses, as well as its global active pharmaceutical ingredient business and generics operations in India. Prior to joining Glenmark, Mr. Coughlin served as Senior Vice President at Dr. Reddy’s Laboratories, Inc. Mr. Coughlin began his career in 1988 with Wyckoff Chemical Company, Inc. Mr. Coughlin earned a B.S. in chemistry from Central Michigan University.

Patrick Barry

Mr. Patrick Barry is the Executive Vice President and Chief Commercial Officer of the company, effective February 26, 2018. In this role, he has responsibility for all commercial activities for U.S. Branded Pharmaceuticals, including strategy, new product planning, marketing, sales as well as managed care and patient access responsibilities. Mr. Barry joined Endo in December 2016 as Senior Vice President, U.S. Branded Pharmaceuticals. Prior to joining Endo, Mr. Barry worked at Sanofi S.A. from April 1992 until December 2016, holding roles of increasing responsibility in areas such as Sales Leadership, Commercial Operations, Marketing, Launch Planning and Training and Leadership Development. Most recently, he served at Sanofi S.A. as its General Manager and Head of North America General Medicines starting in September 2015 and as Vice President and Head of U.S. Specialty from April 2014 until August 2015. During this time, Mr. Barry oversaw three complex and diverse businesses with responsibility for leading sales and marketing activities for branded and generic products across the U.S. and Canada. He has a diverse therapeutic experience including aesthetics and dermatology, oncology, urology, orthopedics and medical device and surgical experience. He has an M.B.A. from Cornell University, Johnson School of Management and a B.A. in Public Relations and Marketing from McKendree University.

Domenico Ciarico

Mr. Domenic Ciarico is Executive Vice President, Chief Commercial Officer - Sterile and Generics of the Company. Prior to joining Endo, Mr. Ciarico spent 20 years with AmerisourceBergen Corporation (ABC), a leading pharmaceutical wholesaler and service provider. At ABC, Mr. Ciarico held several roles of increasing responsibility, including Senior Vice President of Health Systems, leading health systems sales and commercial strategy. Prior to that, Mr. Ciarico was Group Vice President, managing three of ABC's service businesses, including American Health Packaging, Pharmacy Healthcare Solutions and AmerisourceBergen Technology Group. Domenic holds a B.S. degree as well as an M.B.A. from The Ohio State University.

Matthew Maletta

Mr. Matthew Joseph Maletta is an Executive Vice President, Chief Legal Officer of Endo International Public Limited Company. Prior to joining Endo, Mr. Maletta served as Vice President, Associate General Counsel and Corporate Secretary of Allergan, Inc. In this position, he served as an advisor to the CEO and Board of Directors and supervised several large M&A transactions and takeover defense activities, including Allergan’s acquisition of Inamed and Actavis’ acquisition of Allergan. Mr. Maletta first joined Allergan in 2002 as Corporate Counsel and Assistant Secretary and during his tenure, held various roles of increased responsibility. Prior to joining Allergan, Mr. Maletta was in private practice, focusing on general corporate matters, finance, governance, securities and transactions. He holds a B.A. degree in political science from the University of Minnesota, summa cum laude, and a J.D. degree, cum laude, from the University of Minnesota Law School.

Carrie Nichol

Ms. Carrie Ann Nichol is appointed as Chief Accounting Officer, Vice President, Controller of the company effective April 2, 2018. She joined the Company in March 2015 as Director of Consolidations and Financial System and currently serves as Assistant Controller. Prior to joining the Company, Ms. Nichol was SVP & Controller of Haas Group International (now Wesco Aircraft Holdings, Inc.) where she led the global accounting and finance teams from June 2011 until March 2015. Ms. Nichol also played a critical role in Haas Group International’s sale to Wesco Aircraft Holdings, Inc. in 2014. Prior to her employment with Haas Group International, Ms. Nichol was with IKON Office Solutions (now Ricoh Company, Ltd.) for a total of five years from June 2008 until June 2011 and from June 2003 until July 2005, having served most recently as the Director of Financial Reporting and Corporate Accounting where she was responsible for all public filings and technical and corporate accounting. From December 2005 until June 2008, Ms. Nichol was with Advanced Metallurgical Group NV serving as Assistant Controller where she led the integration of several business units in anticipation of the company’s initial public offering. Ms. Nichol began her career in public accounting at KPMG LLP. She is a licensed certified public accountant in the Commonwealth of Pennsylvania and holds a Bachelor of Science degree in Business Management, with a minor in Accounting, from Widener University as well as an M.B.A in Finance from Villanova University.

Shane Cooke

Mr. Shane M. Cooke is an Independent Director of Endo International Public Limited Company. He has been a member of the Board of Directors since July 2014 and is Chair of Endo’s Audit Committee. In March 2018, Mr. Cooke retired from Alkermes plc (Alkermes), most recently having served as its President since 2011, when Elan Drug Technologies (EDT) merged with Alkermes. Mr. Cooke was appointed to the board of directors of Alkermes in March 2018. From 2007 until 2011, he was head of EDT and Executive Vice President of Elan and concurrently served as Chief Financial Officer of Elan Corporation from 2001 to 2011. Mr. Cooke was appointed director of Elan in 2005. Prior to joining Elan, he was Chief Executive of Pembroke Capital Limited, an aviation leasing company of which he was a founder. Mr. Cooke also previously held a number of senior positions in finance in the banking and aviation industries. He currently serves on the boards of directors of Alkermes, Prothena Corporation plc, a publicly traded biotechnology company, and UDG Healthcare plc, a publicly traded company providing healthcare advisory, communications, commercial, clinical and packaging services through its two divisions: Ashfield and Sharp. Mr. Cooke is a chartered accountant and a graduate of University College Dublin, Ireland.

Nancy Hutson

Dr. Nancy J. Hutson, Ph.D., is Independent Directors of Endo International Public Limited Company., since 2009 . She has been a member of the Board of Directors since the Company’s inception in February 2014 and is Chair of Endo’s Compliance Committee and a member of Endo’s Nominating & Governance Committee. Dr. Hutson retired from Pfizer, Inc. (Pfizer) in 2006 after spending 25 years in various research and leadership positions, most recently serving as Senior Vice President, Pfizer Global Research and Development and Director of Pfizer’s pharmaceutical R&D site, known as Groton/New London Laboratories, the largest R&D site of any pharmaceutical company. At Pfizer, she led 4,500 colleagues (primarily scientists) and managed a budget in excess of $1 billion. She is currently a Director of BioCryst Pharmaceuticals, Inc. and PhaseBio Pharmaceuticals, Inc. Dr. Huston previously served as Director of Cubist Pharmaceuticals until 2015 and Inspire Pharmaceuticals, Inc. until 2011. From 2009 until February 2014, Dr. Hutson was a Director of Endo Health Solutions Inc. Dr. Hutson owns and operates Standing Stones Farm in Ledyard, CT, which is dedicated to supporting the equestrian sport of dressage. Dr. Hutson holds a Bachelor of Arts degree from Illinois Wesleyan University and a Ph.D. degree from Vanderbilt University.

Michael Hyatt

Mr. Michael Hyatt is an Independent Director of Endo International Public Limited Company. He has been a member of the Board of Directors since the Company’s inception in February 2014 and is a member of Endo’s Compensation Committee and an alternate member of the Nominating & Governance Committee. Mr. Hyatt is currently a Senior Advisor to Irving Place Capital, a leading institutional private equity firm focused on making equity investments in middle-market companies. Prior to joining Irving Place Capital in 2008, Mr. Hyatt was a Senior Managing Director of Bear Stearns & Co., Inc. Mr. Hyatt previously served as a Director of Schiff Nutrition International until 2012. From 2000 until February 2014, Mr. Hyatt was a Director of Endo Health Solutions Inc. Mr. Hyatt holds a Bachelor of Arts degree from Syracuse University and a J.D. degree, from Emory University School of Law.

Sharad Mansukani

Dr. Sharad S. Mansukani, M.D. is Senior Independent Director of the company. Dr. Mansukani has been serving as a senior advisor of TPG Capital LP since 2005. From 2012 to 2015, Dr. Mansukani served as a strategic advisor to the board of directors of Cigna Corp. Prior to his position at Cigna Corp., Dr. Mansukani was appointed to Medicare’s Program Advisory and Oversight Committee by the Secretary of the Department of Health and Human Services from 2009 to 2012. Dr. Mansukani also served as a senior advisor to the Administrator of the Centers for Medicare and Medicaid Services (CMS) from 2003 to 2005, where he advised on design and implementation of the Medicare pre-scription drug benefit, also known as Medicare Part D. Prior to CMS, Dr. Mansukani was a senior vice president and chief medical officer at Health Partners from 1999 to 2003. Previously, Dr. Mansukani served as the vice chairman of the board of directors of Health Spring Inc. from 2007 to 2012 and as chairman of the board of directors of Envision Rx Options from 2013 to 2016. Dr. Mansukani also served on the boards of directors of Kindred Healthcare Inc. from 2015 to 2018, Surgical Care Affiliates, Inc. from 2007 to 2017, IASIS Healthcare Corporation from 2005 to 2017, IMS Health Holdings, Inc. from 2009 to 2016 and Par Pharmaceutical Holdings, Inc. from 2012 to 2015, prior to the Company’s acquisition of Par Pharmaceutical Holdings, Inc. in 2015. Dr. Mansukani currently serves on the board of directors of the Children’s Hospital of Philadelphia. Dr. Mansukani is qualified to serve on the Board of the Company based on his extensive knowledge of the pharmaceutical industry and service as a board member of publicly traded and private companies in the industry and based on his in-depth knowledge and understanding of the complex U.S. healthcare system.

William Montague

Mr. William P. Montague, is Independent Director of Endo International Public Limited Company. Mr. Montague served as Chief Executive Officer of Mark IV Industries, Inc., a leading global diversified manufacturer of highly engineered systems and components for transportation infrastructure, vehicles and equipment, from 2004 until his retirement in 2008 and as Director from 1996. He joined Mark IV Industries in 1972 as Treasurer/Controller, serving as Vice President of Finance from 1974 to 1986, then Executive Vice President and Chief Financial Officer from 1986 to 1996 and then as President from 1996 to 2004. Mr. Montague is also a Director of Gibraltar Industries, Inc., a publicly traded manufacturer and distributor of products for the building and industrial markets since 1993, and has served as Chairman of Gibraltar’s Board of Directors since 2015. From 2013 until 2014, Mr. Montague served as a Director of Allied Motion Technologies Inc., a publicly traded company focused exclusively on serving the motion control market. From 2009 until February 2014, Mr. Montague was a Director of Endo Health Solutions Inc. Mr. Montague is a Certified Public Accountant; he holds a Bachelor of Science degree in accounting and an M.B.A. from Wilkes University.

Basic Compensation

Name Fiscal Year Total

Roger Kimmel

450,000

Paul Campanelli

19,970,700

Blaise Coleman

2,635,660

Terrance Coughlin

3,129,450

Patrick Barry

--

Domenico Ciarico

--

Matthew Maletta

2,551,130

Carrie Nichol

--

Shane Cooke

325,000

Nancy Hutson

320,000

Michael Hyatt

315,000

Sharad Mansukani

360,000

William Montague

320,000
As Of  31 Dec 2018